SCHEMBL2763601

SCHEMBL2763601

OC(Cl)Cc1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.56
SLC6A2 P23975 1/20 0.52
SLC6A3 Q01959 1/20 0.52
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
IDO1 P14902 3/20 0.44
CYP2D6 P10635 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
TAAR1 Q96RJ0 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.40
CYP2A6 P11509 1/20 0.40
GAA P10253 1/20 0.40
AGXT P21549 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4297795 0.82 SLC6A2 (0.60) SLC6A4SLC6A2SLC6A3PPARGPPARA
SCHEMBL9481333 0.82 SLC6A4 (0.58) SLC6A4SLC6A2SLC6A3PPARGPPARA
SCHEMBL8322312 0.79 SLC6A4 (0.61) SLC6A4SLC6A2SLC6A3PPARGPPARA
SCHEMBL4161150 0.78 SLC6A2 (0.61) SLC6A4SLC6A2SLC6A3PPARGPPARA
SCHEMBL1253523 0.78 SLC6A4 (0.54) SLC6A4SLC6A2SLC6A3PPARGPPARA
SCHEMBL5099590 0.78 SLC6A4 (0.54) SLC6A4SLC6A2SLC6A3PPARGPPARA
SCHEMBL10763436 0.78 SLC6A4 (0.67) SLC6A4SLC6A2SLC6A3PPARGPPARA
SCHEMBL4158699 0.78 SLC6A2 (0.61) SLC6A4SLC6A2SLC6A3PPARGPPARA
SCHEMBL19616116 0.78 SLC6A4 (0.54) SLC6A4SLC6A2SLC6A3PPARGPPARA
SCHEMBL28771419 0.78 SLC6A4 (0.54) SLC6A4SLC6A2SLC6A3PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6989052-B1 Phase change ink printing process XEROX CORPORATION (US) 2006-01-24 US claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 US claimed
EP-3881048-B1 DEVICE FOR REMOVING VOLATILE ORGANIC COMPOUNDS LETAT FRANCAIS REPRESENTE PAR LE MINI DE LINTERIEUR (FR) 2026-05-06 EP disclosed
US-20210396629-A1 DEVICE FOR COLLECTING VOLATILE ORGANIC COMPOUNDS L'ETAT FRANÇAIS REPRÉSENTÉ PAR LE MINISTÈRE DE L'INTÉRIEUR (FR) 2021-12-23 US disclosed
EP-3881048-A1 DEVICE FOR REMOVING VOLATILE ORGANIC COMPOUNDS L'etat Français Représenté Par Le Ministère De L'intérieur (FR) 2021-09-22 EP disclosed
CN-113167695-A Device for collecting volatile organic compounds 法国由内政部代表 2021-07-23 CN disclosed
WO-2020099735-A1 DEVICE FOR REMOVING VOLATILE ORGANIC COMPOUNDS L'ETAT FRANÇAIS REPRÉSENTÉ PAR LE MINISTÈRE DE L'INTÉRIEUR (FR) 2020-05-22 WO disclosed
US-20130072497-A1 N- SUBSTITUTED PIPERAZINES DOW AGROSCIENCES LLC (US) 2013-03-21 US disclosed
US-8338430-B2 N-substituted piperazines DOW AGROSCIENCES, LLC. (US) 2012-12-25 US disclosed
EP-1474387-B1 DERIVATIVES OF ALPHA-PHENYLTHIOCARBOXYLIC AND ALPHA-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPAR ALPHA ACTIVATION SIGMA TAU IND FARMACEUTI (IT) 2010-11-24 EP disclosed
US-20100234391-A1 N-SUBSTITUTED PIPERAZINES DOW AGROSCIENCES LLC (US) 2010-09-16 US disclosed
EP-1474387-A2 DERIVATIVES OF ALPHA-PHENYLTHIOCARBOXYLIC AND ALPHA-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPAR ALPHA ACTIVATION Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 2004-11-10 EP disclosed
US-20040102634-A1 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-05-27 US disclosed
EP-1380562-A1 CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed
EP-1345900-A1 GUANIDINE AND AMIDINE DERIVATIVES AS FACTOR XA INHIBITORS Sanofi-Aventis Deutschland GmbH (DE) 2003-09-24 EP disclosed
WO-2003059875-A2 DERIVATIVES OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPARα ACTIVATION SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2003-07-24 WO disclosed
US-20020173656-A1 Guanidine and amidine derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-11-21 US disclosed
WO-2002046159-A1 GUANIDINE AND AMIDINE DERIVATIVES AS FACTOR XA INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-06-13 WO disclosed
EP-0258391-A1 USE OF HETEROCYCLIC NITROGEN-CONTAINING COMPOUNDS FOR REDUCING MOISTURE LOSS FROM PLANTS AND INCREASING CROP YIELD RHONE POULENC NEDERLAND B.V. (NL) 1988-03-09 EP disclosed
WO-1987004321-A2 USE OF HETEROCYCLIC NITROGEN-CONTAINING COMPOUNDS FOR REDUCING MOISTURE LOSS FROM PLANTS AND INCREASING CROP YIELD RHONE-POULENC NEDERLANDS B.V. (NL) 1987-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234391-A1 N-SUBSTITUTED PIPERAZINES PRXL2A, CNPY2, CYP4X1 SLC6A4 3467/4885SLC6A2 3607/4885SLC6A3 3350/4885
US-20020173656-A1 Guanidine and amidine derivatives as factor Xa inhibitors F5, F9, F10 SLC6A4 4271/4885SLC6A2 3613/4885SLC6A3 4314/4885
US-20040102634-A1 Carboxylic acid derivative and salt thereof GPR119, IRS1, SLC5A1 SLC6A4 829/4885SLC6A2 957/4885SLC6A3 959/4885
US-20130072497-A1 N- SUBSTITUTED PIPERAZINES PRXL2A, CNPY2, CYP4X1 SLC6A4 3467/4885SLC6A2 3607/4885SLC6A3 3350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.